'M0 patients' diaporamas de présentation

STAMPEDE Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy

STAMPEDE Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy. Sponsor number: MRC PR08 ISRCTN number: ISRCTN78818544 EUDRACT number: 2004-000193-31 CTA number: 00316/0026/001-0001. STAMPEDE uses multi-arm multi-stage methodology

963 views • 66 slides

STAMPEDE Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy

STAMPEDE Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy. Sponsor number: MRC PR08 ISRCTN number: ISRCTN78818544 EUDRACT number: 2004-000193-31 CTA number: 00316/0026/001-0001. STAMPEDE uses multi-arm multi-stage methodology

970 views • 66 slides

STAMPEDE Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy

STAMPEDE Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy. Charlene Green STAMPEDE Clinical Trial Manager. Sponsor number: MRC PR08 ISRCTN number: ISRCTN78818544 EUDRACT number: 2004-000193-31 CTA number: 00316/0026/001-0001.

1.06k views • 43 slides

STAMPEDE trial (MRC PR08): Arm J overview

989 views • 39 slides

STAMPEDE Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy

STAMPEDE Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy. How to report Progressions and RT data. Sponsor number: MRC PR08 ISRCTN number: ISRCTN78818544 EUDRACT number: 2004-000193-31 CTA number: 00316/0026/001-0001.

598 views • 39 slides

STAMPEDE trial (MRC PR08): Arm J Pharmacy Training

STAMPEDE trial (MRC PR08): Arm J Pharmacy Training. Overview. Arm J Hypothesis and trial design Activation timelines and requirements Treatment administration and duration IMPs overview Configuration Drug ordering Accountability Destruction Returns Other pharmacy updates.

441 views • 25 slides